Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant therapy for extremity sarcomas.

Michael Schlieman1, Richard Smith, William G Kraybill

  • 1Roswell Park Cancer Institute, Elm and Carlton Streets, Carlton Building Room #252, Buffalo, NY 14263, USA.

Current Treatment Options in Oncology
|October 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expanding Public Health Policy Analysis for Transformative Change: The Importance of Power and Ideas Comment on "What Generates Attention to Health in Trade Policy-Making? Lessons From Success in Tobacco Control and Access to Medicines: A Qualitative Study of Australia and the (Comprehensive and Progressive) Trans-Pacific Partnership".

International journal of health policy and management·2020
Same author

Multi-institutional Comparison of Temporal Bone Models: A Collaboration of the AAO-HNSF 3D-Printed Temporal Bone Working Group.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2020
Same author

Innovations present in the primate interneuron repertoire.

Nature·2020
Same author

Thai version of the foot function index: a cross-cultural adaptation with reliability and validity evaluation.

BMC sports science, medicine & rehabilitation·2020
Same author

Performance evaluation of a small-scale digester for achieving decentralised management of waste.

Waste management (New York, N.Y.)·2020
Same author

Screening an Established Natural Product Library Identifies Secondary Metabolites That Potentiate Conventional Antibiotics.

ACS infectious diseases·2020
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Surgery is the primary treatment for extremity soft tissue sarcomas (STS). While radiotherapy improves local control, chemotherapy

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Extremity soft tissue sarcomas (STS) are rare, heterogeneous malignancies.
  • Surgery is the primary treatment, with radiotherapy improving local control for advanced cases.
  • The role of adjuvant chemotherapy in high-risk STS remains debated due to limited survival benefits.

Purpose of the Study:

  • To review current treatment strategies for extremity soft tissue sarcomas.
  • To evaluate the efficacy and toxicity of neoadjuvant chemotherapy and targeted therapies.
  • To provide recommendations for managing high-risk extremity STS.

Main Methods:

  • Review of existing literature on surgical, radiotherapeutic, and chemotherapeutic approaches for STS.
  • Analysis of data from clinical trials investigating neoadjuvant chemotherapy regimens (e.g., mesna, doxorubicin, ifosfamide, dacarbazine).

Related Experiment Videos

  • Assessment of the limited success of targeted therapies in extremity STS.

    • Main Results:

    • Surgery achieves adequate margins for small, low-grade tumors; radiotherapy enhances local control for larger tumors.
    • Neoadjuvant chemotherapy shows early promise but is associated with increased toxicity.
    • Targeted therapy has demonstrated limited efficacy in extremity STS compared to other cancers.

    Conclusions:

    • High-dose adjuvant or neoadjuvant chemotherapy should be considered within clinical trials for high-risk STS patients.
    • Future research should focus on novel combination therapies, including targeted agents, for large, high-grade STS.
    • Clinical trial participation is crucial for advancing the management of high-risk extremity soft tissue sarcomas.